Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Paclitaxel (DHP107) vs IV Paclitaxel in HER2-Negative Recurrent/Metastatic Breast Cancer
2024-517090-24-00Phase 3Authorised
- Sponsor
- Daehwa Pharmaceutical Co., Ltd.
- Start
- Oct 2024
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of NanoPac in breast cancer (2 arms), sponsored by Daehwa Pharmaceutical Co., Ltd. Primary endpoint: Progression-free survival. Planned start Oct 2024; status: authorised.
02
Drugs
NanoPac
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-517090-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517090-24-00.